FHLC vs XPH: A 26-Point Gap That's a Concentration Bet, Not a Better Fund

Give each fund $100 in paper points a year ago. Watch what's there today. State Street's SPDR S&P Pharmaceuticals ETF (XPH) is worth about $148. Fidelity's MSCI Health Care Index ETF (FHLC) — the broad healthcare basket — is worth about $122.

Same starting bell, same finish, same sector. Per recent market data, XPH is up roughly 48% over the past year; FHLC is up about 22%. (This year so far the split looks similar, about 23% to 9%.) Both own Eli Lilly, Johnson & Johnson, Merck, and AbbVie as core names. So how do two funds holding the same top stocks end up 26 points apart?

The quick answer is "XPH is just the better fund." The more useful answer is that the gap is not a quality gap at all. It is a concentration gap: XPH bets the whole fund on the one slice of healthcare — pharmaceuticals — that has been the hottest trade in the market this year. FHLC spreads those same winners across devices, diagnostics, and insurers, and that extra diversification is exactly what holds its number back.

Forget which fund sounds better. The match turns on what each one actually holds — and what that bet costs you when the boom cools.

The card

FHLC is a broad U.S. healthcare fund. It holds roughly 340 companies across the whole sector — drugmakers, medical-device makers, diagnostics, and insurers — and tracks a broad MSCI U.S. healthcare index. Its biggest positions are Eli Lilly at about 13%, then Johnson & Johnson near 9%, AbbVie near 6%, UnitedHealth near 5%, and Merck near 5%. Its fee is 0.084% a year, and it pays a yield of about 1.3%.

XPH is far narrower. It holds the S&P 500's large-cap pharmaceutical companies — around 50 drugmakers, and drugmakers only. It owns those same heavyweights (Lilly, J&J, Merck, AbbVie) but none of the rest of healthcare. Its fee is 0.35% a year, four times FHLC's, and its yield is a slimmer 0.5%.

So this is not a "good fund versus bad fund" race. It is one slice of the sector versus the whole sector. For a beginner: the fee, called the expense ratio, is charged as a percentage of your investment each year — on $1,000 you'd pay about $0.84 with FHLC and about $3.50 with XPH. Small now, but fees compound over the years you hold.

On the card as it stands, XPH opens as the clear favorite — it's up nearly twice as much. But the handicap is on the fee and the concentration, not on quality, and that distinction drives the whole read.

Why the pharma slice is on fire

The pharma engine ran hot this year, and that is the mechanism behind the gap. Through August, the S&P 500's pharmaceutical index had risen about 18% year-to-date, against the wider S&P 500's 13%. The gap widened in the summer: since May, pharma was up roughly 19% to the index's 7%.

Three forces are doing the pushing. First, money is rotating out of the stretched generative-AI trade and into what traders call a "defensive halo" — industries whose core work can't be automated. A Barclays analyst framed pharma as an "AI winner" that steadies a portfolio when tech gets nervous. Second, the White House drug-pricing deals (led by Lilly, Novo Nordisk, and AstraZeneca) swapped lower U.S. prices for tariff relief and largely removed the policy uncertainty that had capped the sector. Third, there is a real product story: Eli Lilly, the biggest name in both funds, leads the booming GLP-1 weight-loss and diabetes market and is buying aggressively — taking on Kelonia and Centessa in deals worth about $7 to $8 billion each.

XPH is 100% pharma, so it caught all of that with nothing diluting it. FHLC caught it too — Lilly is its top holding — but its device, diagnostics, and insurer names moved more slowly, so the fund's total came in lower. That is most of the 26 points, and that is the whole mechanism.

The flip side

Here is the part the scoreboard hides. The gap is a timing gap, not a permanent edge. It exists because pharma is the hot sub-sector right now. If the AI-rotation cools, or the GLP-1 story hits a stumble — a trial miss, a pricing crackdown, a rival's better drug — the concentrated fund has more to fall than the diversified one.

FHLC's diversification is the hedge. Take UnitedHealth, the insurer FHLC owns and XPH does not. It had a brutal 2025: it reported just $10 million of fourth-quarter profit, its stock fell about 16% in the open, and it warned it would lose roughly 1.3 million Medicare Advantage members this year. That drag is part of why FHLC lagged. But it is also the counter-argument: UNH has since bounced about 20% year-to-date. The non-pharma names that trailed can catch up — and they can also sink when pharma rallies. XPH never gets that balance, in either direction.

Then the fee and the income. Paying 0.35% instead of 0.084% is invisible on a one-year hot streak and compounds against the expensive fund over a decade. And FHLC pays you more to hold it — a 1.3% yield against 0.5%.

The score

Two scoreboards, and they point in different directions. The return scoreboard: XPH wins, decisively, on the past year — about 48% to 22%. The mechanism scoreboard: XPH's win came from concentrating on the market's hottest sub-sector, not from a structurally superior fund. The same top names drove both; the difference is what the rest of each portfolio does.

So the "better buy" is less a fund choice than a bet. Do you want the pure engine (XPH) — maximum exposure to the pharma boom, more volatility, a higher fee — or the whole sector (FHLC) — diversified, cheaper, a small income, and built to survive the day the boom cools?

The design lesson is short: a one-year gap between two funds that hold the same top names is a concentration statement, not a quality statement. Don't pay four times the fee for the privilege of betting that one sub-sector stays on fire.

The next thing that decides this match is the AI-rotation itself. While investors keep treating pharma as the safe exit from stretched tech, XPH keeps the lead. The moment that trade unwinds — or the GLP-1 leaders falter — the 26-point gap is the first thing to give back.